Viridian Therapeutics, Inc. Stock price

Equities

VRDN

US92790C1045

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
17.51 USD 0.00% Intraday chart for Viridian Therapeutics, Inc. -6.76% -19.61%
Sales 2024 * 307K Sales 2025 * 3.11M Capitalization 1.1B
Net income 2024 * -266M Net income 2025 * -293M EV / Sales 2024 * 2,218 x
Net cash position 2024 * 418M Net cash position 2025 * 587M EV / Sales 2025 * 165 x
P/E ratio 2024 *
-3.98 x
P/E ratio 2025 *
-4.03 x
Employees 94
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.57%
More Fundamentals * Assessed data
Dynamic Chart
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers MT
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000 MT
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer MT
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer CI
Wedbush Trims Viridian Therapeutics' Price Target to $39 From $40, Keeps Outperform Rating MT
Viridian Therapeutics Prices Common Stock Offering at $21 per Share MT
Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours MT
Transcript : Viridian Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM
Viridian Therapeutics, Inc. Provides Key Updates on its Anti-Insulin-Like Growth Factor 1 Receptor (IGF-1R) Programs in Thyroid Eye Disease and its Programs Targeting FcRn CI
Viridian Therapeutics, Inc. Announces Executive Changes CI
Oppenheimer Raises Viridian Therapeutics Price Target to $36 From $35, Maintains Outperform Rating MT
Wedbush Raises Viridian Therapeutics' PT to $40 From $37, Keeps Outperform Rating; Says Remains Among a Top Pick Into 2024 MT
More news
1 week-6.76%
Current month-6.41%
1 month-13.19%
3 months-21.80%
6 months+15.50%
Current year-19.61%
More quotes
1 week
17.14
Extreme 17.14
18.33
1 month
16.16
Extreme 16.16
20.50
Current year
16.16
Extreme 16.16
24.18
1 year
10.93
Extreme 10.925
30.30
3 years
9.47
Extreme 9.47
39.00
5 years
4.67
Extreme 4.665
48.90
10 years
4.67
Extreme 4.665
270.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 23-10-29
Director of Finance/CFO 45 23-04-30
Chief Tech/Sci/R&D Officer 59 22-12-31
Members of the board TitleAgeSince
Director/Board Member 72 18-01-02
Chairman 38 20-10-27
Chief Executive Officer 53 23-10-29
More insiders
Date Price Change Volume
24-03-28 17.51 0.00% 1,010,508
24-03-27 17.51 +0.81% 707,739
24-03-26 17.37 -1.03% 621,252
24-03-25 17.55 -2.55% 921,860
24-03-22 18.01 -4.10% 849,852

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
17.51 USD
Average target price
39.36 USD
Spread / Average Target
+124.77%
Consensus
  1. Stock
  2. Equities
  3. Stock Viridian Therapeutics, Inc. - Nasdaq